PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of neurologyNeurologyAmerican Academy of Neurology
 
Neurology. Aug 14, 2012; 79(7): 659–667.
PMCID: PMC3414661
Large-scale replication and heterogeneity in Parkinson disease genetic loci
Manu Sharma, PhD,corresponding author
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
John P.A. Ioannidis, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • Editor-in-chief, European Journal of Clinical Investigation Editorial board member: Lancet (2005-) ·Journal of the National Cancer Institute (2005-) ·Annals of Internal Medicine (2007-2010) ·PLoS Medicine (2007-) ·AIDS (2004-2007, 2007-2010) ·International Journal of Epidemiology (2007-) ·Cochrane Library (1998-), editor, HIV/AIDS CRG ·Cancer Treatment Reviews (2006-)· Guest editor, Seminars in Hematology (2008 issue) ·Journal of Clinical Epidemiology (2005-) ·BioMed Central Infectious Diseases (2000-) ·BioMed Central Medical Research Methodology (2000- ) ·Clinical Trials (was Controlled Clinical Trials, 2004-) ·Journal of Evaluation in Clinical Practice (2008-) ·Journal of Empirical Research in Human Research Ethics (2006-) ·PLoS ONE (2006-) ·Annals of Gastroenterology; ·Open Medicine (2007-) ·Cases Journal (2008-2010) ·Human Genomics and Proteomics (2008-) ·Research Synthesis Methods (2008-, first issue in 2010) ·GAPP Reviews (2009-); currently PLoS Currents: Evidence on Genomic Tests ·International Journal of Molecular Epidemiology and Genetics (2009-) ·Italian Journal of Public Health (2009-) ·LER (Letter to the editor in rheumatology) (2010-)
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • EU FP6, FP7 NIH Canadian Institutes for Health Research
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Jan O. Aasly, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • Parkinsonism and related disorders; Parkinson’s disease; J Norwegian Medical Association ;
Patents:
  • Patent for LRRK2 G2019S
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Grazia Annesi, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Alexis Brice, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • The Lancet Neurology (2003-2010); Brain (2007-); Human Molecular Genetics (2005-); Neurodegenerative Diseases (2003-); Neurogenetics (2001-); Journal of Neurology (1998-2003); European Neurology (1998-2009); Neuromuscular Disorders (1998-2000); The Cerebellum (2001-); La Revue Neurologique (1997-2005); Parkinsonism and Related Disorders (2008-)
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • French Agency for Research; Programme Hospitalier de Recherche Clinique; Michael J. Fox Foundation; French Association Against Myopathies
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Christine Van Broeckhoven, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Lars Bertram, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • Neurogenetics, Associate Editor, since 2007 European Journal of Clinical Investigation, Associate Editor, since 2009 International Journal of Molecular Epidemiology and Genetics, Associate Editor, since 2010 International Journal of Alzheimer’s Disease, Guest editor, 2010-2011
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Maria Bozi, MD,
Scientific Advisory Boards:
  • UCB
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
David Crosiers, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • Abbott, travel and accommodation expenses for attending scientific congress; Boehringer Ingelheim, travel and accommodation expenses for attending scientific congress
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • Research Foundation Flanders (FWO), 1129212N, PhD fellowship, 2009-2013
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Carl Clarke, MD,
Scientific Advisory Boards:
  • Commercial - Abbott, GlaxoSmithKline, and UCB. Non-commercial - Chairman of EMPIRE DSMB.
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • Commercial - Abbott, GlaxoSmithKline, Orion Pharma, Teva, and UCB
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NIHR Health Technology Assessment Programme for PD MED and PD REHAB clinical trials.
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Maurizio Facheris, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Matthew Farrer, PhD,
Scientific Advisory Boards:
  • Michael J. Fox Foundation, SAB member since 2002
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • Neurobiology of Disease, editorial board member, 2006- 2008 Parkinsonism & related disorders, editorial board member, 2008-present
Patents:
  • Lrrk2 gene and mutations. a)International Publication Number WO 2006/045392 A2; (b) International Publication Number WO 2006/068492 A1; (c) US Patent Number 7,544,786; and (d) Norwegian patent 323175 -provisionally filed in 2004-2005
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • Sponsored research agreement between Lundbeck Inc. and Mayo, for Lrrk2 mouse model characterization, 2008-2011
Research Support, Government Entities:
  • NIH, NS40256, Project and Core PI, 2004-2009 Canadaian Federal Government (CERC, CFI)
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • Pacific Alzheimer Research Foundation, Core PI, 2008-2009 Michael J Fox Foundation, LEAPS PI, 2008-2009
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • Lundbeck Inc. for Lrrk2 mouse model characterization, 2008-2011
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Gaetan Garraux, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Suzana Gispert, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • Bildungsministerium für Bildung und Forschung
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Georg Auburger, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • Cerebrovascular Diseases, Editorial Board, 2009-2011; ISRN Neurology, Editorial Board, 2011
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Carles Vilariño-Güell, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Georgios M. Hadjigeorgiou, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Andrew A. Hicks, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Nobutaka Hattori, MD, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • Movement Disorders, Journal of Neural Transmission
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Beom Jeon, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • funding for travel from Medtronics Korea, GlaxoSmithKline Korea and Novartis Korea; and has received research support as PI from Norvartis, Boehringer Ingelheim, Ipsen Korea.
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (#A030001), ABRC (Advanced Biometric Research Center),KOSEF (Korea Science and Engineering Foundation),
Research Support, Academic Entities:
  • Seoul National University Hospital
Research Support, Foundations and Societies:
  • the Mr. Chung Suk-Gyoo and Sinyang Cultural Foundation, and the Song Foundation.
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Suzanne Lesage, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Christina M. Lill, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Juei-Jueng Lin, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Timothy Lynch, MD,
Scientific Advisory Boards:
  • 1. Novartis, Fingolimod Advisory Board Ireland 2. Abbott, Duodopa Advisory Board Ireland
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • Funding for travel and speaking from Boeringher Ingelheim, Parkinson’s disease meeting London 2011.
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • 1. Lundbeck unrestricted educational grant. 2. Elan Pharma Corporation unrestricted grant for the Dublin Neurological Institute. 3. Bayer Schering and Biogen Idec pharmaceutical grants for funding for staff at the Dublin Neurological Institute.
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • 1. Irish Institute of Clinical Neuroscience 2 year grant for €100,000 2. Mater College
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Peter Lichtner, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Anthony E. Lang, MD,
Scientific Advisory Boards:
  • Dr. Lang has served as an advisor for Abbott, Allon Therapeutics, Biovail, Boerhinger-Ingelheim, Cephalon, Ceregene, Eisai, Medtronic, Lundbeck A/S, NeuroMolecular, Novartis, Merck Serono, Solvay, and Teva, and received grants from Canadian Institutes of Health Research, Dystonia Medical Research Foundation, Michael J. Fox Foundation, National Parkinson Foundation, Ontario Problem Gambling Research Centre, Parkinson’s Disease Foundation.
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • Schapira A, Lang AE, Fahn S. Movement Disorders 4. Saunders, Elsevier, Philadelphia, PA 2009. Olanow CW, Stocchi F, Lang AE. The Non-motor and Non- Dopaminergic Features of Parkinson’s Disease. Wiley- Blackwell, UK. 2011. Weiner WJ, Shulman LM, Lang AE. Parkinson’s Disease: A Complete Guide for Patients and Families. The Johns Hopkins University Press, Baltimore. 2001
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • Canadian Institutes of Health Research,
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • Dystonia Medical Research Foundation, Michael J. Fox Foundation, National Parkinson Foundation, Ontario Problem Gambling Research Centre, Parkinson’s Disease Foundation, and
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • Welding rod companies
Vincent Mok, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Barbara Jasinska-Myga, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • the Medical University of Silesia, Poland (one year:2008/2009)
Research Support, Foundations and Societies:
  • the Robert and Clarice Smith Fellowship Program (one year:2008/2009); the Pacific Alzheimer Research Foundation (PARF) C06-01 grant (one year:2008/2009); the Polish Foundation for Development of Neurology, Degenerative and Cerebrovascular Diseases;
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
George D. Mellick, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • Australian National Health and Medical Research Council, APP1010225, PI, 2011-2013.
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • Geriatric Medical Foundation of Queensland; Parkinson’s Queensland Incorporated
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Karen E. Morrison, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • Neurodegenerative Disease Management, Editorial Board Member, since 2010.
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • Consultant for TauRx Therapeutics
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • Midlands Neuroscience Teaching and Research Fund
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Grzegorz Opala, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Peter P. Pramstaller, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • Parkinsonism and Related Disorders 2009
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Irene Pichler, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Sung Sup Park, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • This study was in part supported by a grant from the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (A030001)
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Aldo Quattrone, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • Neurological Sciences, Associate Editor
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Ekaterina Rogaeva, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Owen A. Ross, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • Open Longevity Science , Editorial Board, 2008-present PLoS ONE, Editorial Board, 2010-present
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Leonidas Stefanis, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • 1. Journal of Neuroscience, Editor, 2008- 2. Journal of Biological Chemistry, Editor, 2009-
Patents:
  • NONE
Publishing Royalties:
  • 1. Merritt’s Textbook of Neurology, 2009 2. Encyclopedia of Movement Disorders, 2010
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • 1. GlaxoSmithKline Hellas award for the study of the genetics of Parkinson’s Disease in Greece, 2010
Research Support, Government Entities:
  • 1. Hellenic General Secretariat of Research and Technology, Models of dysfunction of the ubiquitin- proteasome system in neurons, PI, 2007-2009 2. Hellenic Ministry of Health, Correlation of Gaucher’s Disease to alpha-synuclein and Parkinson’s Disease, PI, 2010-2011 3. European Union, Initial Training Network, NEURASYN, PI, 2009-2013 4. European Union, Cooperation Grant: MEFOPA, 2010-2013 5. Hellenic General Secretariat of Research and Technology,PhD Studentship: Transcriptional regulation of alpha-synuclein. PI, 2011-2014
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • 1. Michael J. Fox Foundation, Selective neuroprotective effects of the polymorphic variant S18Y of UCH-L1, 2008- 2009
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Joanne D. Stockton, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Wataru Satake, MD, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Peter A. Silburn, MD,
Scientific Advisory Boards:
  • National Health and Medical Research Council of Australia , Member Principle Research Committee , 2006- 2009 . Novartis Australia Stalevo Scientific Advisory board, member , Ongoing . Boehringer Ingelheim Australia Sifrol Advisory Board , member , ongoing . Schwarz Pharma Australia Neupro Advisory Panel , member , ongoing .
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • Merck Serono , attendance World Neurology Conference 2009. Novartis , attendance European Federation Neurological Societies Annual meeting ,2009. Merck Serono , attendance at American Academy Neurology Annual meeting Hawaii 2011
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • National Health and Medical Research Council of Australia , one grant , Chief investigator ,2006-2009 .\ Australian research Council grant 2011-2114
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Jessie Theuns, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • Research Foundation Flanders (FWO), Research grant G.0085.08; co-PI.; Research Foundation Flanders (FWO), Belgium; Postdoctoral Fellowship; PI.; Agency for Innovation by Science and Technology - Flanders (IWT), Research grant 080020, co-PI.; Flemish Government, Belgium; Methusalem excellence grant; key personnel.; Belgian Science Policy Office; Interuniversity Attraction Poles program (IUAP) P6/43; key personnel.; University of Antwerp, Belgium; Special Research Fund; key personnel
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • Foundation for Alzheimer Research (SAO-FRMA), Belgium; Research Grant #09007; PI.; Alzheimer’s Association, USA; New Investigator Research Grant, NIRG-09-132000; PI.; Belgian Parkinson Foundation, Belgium; Research grant; PI.
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Eng-King Tan, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • Have received honoraria from GSK, Lunbeck, Boeringher, Norvatis
Editorial Boards:
  • European Journal of Neurology (associate editor), Parkinsonism Related Disorders (associate editor), Basal Ganglia (associate Editor), Annals Academy of Medicine (Editor), Journal of Parkinson’s disease (board member), Tremor and Hyperkinetic Disorder (board member)
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • National Medical Research Council, Singapore Millennium Foundation, Duke NUS Graduate Medical School
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Tatsushi Toda, MD, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • Grant-in-Aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan. Grants-in-Aid from the Research on intractable diseases, the Ministry of Health, Labour and Welfare of Japan.
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Hiroyuki Tomiyama, MD, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Ryan J. Uitti, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • Associate Editor-Neurology
Patents:
  • LRRK2-Mayo Clinic
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • ANS 2007-2009 research study
Research Support, Government Entities:
  • NINDS-Udall Center 2004-2009
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • PARFF 2008-2009
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Karin Wirdefeldt, MD, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Zbigniew Wszolek, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • Parkinsonism and Related Disorder, Co-Editor-in Chief, 2008-present; European Journal of Neurology, Regional Editor, 2007-present; Advances in Rehabilitation, Editorial Board member, 2005-present; Medical Journal of the Rzeszow University and the National Medicines Institute, Editorial Board member, 2005-present; Clinical and Experimental Medical Letters, Editorial Board member, 2006-present.
Patents:
  • Identification of Mutations in PARK8, a Locus for Familial Parkinson’s Disease, Mayo Clinic case #2004-185; Identification of a Novel LRRK2 Mutation, 6055G>A (G2019S), Linked to Autosomal Dominant Parkinsonism in Families from Several European Populations, Mayo Clinic case #2004-291
Publishing Royalties:
  • Parkinsonism and Related Disorders, Elsevier, 2009, 2010, 2011; European Journal of Neurology, Wiley-Blackwell, 2009, 2010, 2011.
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NIH/NINDS 1RC2NS070276, NS057567, P50 NS072187, P50 NS072187-01S2
Research Support, Academic Entities:
  • Mayo Clinic Florida (MCF) Research Committee CR programs (MCF #90052018 and MCF #90052030)
Research Support, Foundations and Societies:
  • Dystonia Medical Research Foundation
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • Mayo Clinic and I have a financial interest in technologies entitled, “Identification of Mutations in PARK8, a Locus for Familial Parkinson’s Disease” and “Identification of a Novel LRRK2 Mutation, 6055G>A (G2019S), Linked to Autosomal Dominant Parkinsonism in Families from Several European Populations”. Those technologies have been licensed to a commercial entity, and to date, I have received royalties through Mayo Clinic in accordance with its royalty sharing policies.
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Georgia Xiromerisiou, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Kuo-Chu Yueh, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Yi Zhao, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Thomas Gasser, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • Parkinsonism and Related Disorders, editorial board member, since 2007; Movement Disorders, editorial board member; Journal of Neurology, editorial board member
Patents:
  • KASPP (LRRK2) Gene, its Production and Use for the Detection and Treatment of Neurodegenerative Diseases
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • Cefalon Pharma; Merck-Serono Speakers’ Bureaus:; Novartis; Merck-Serono; Schwarz Pharma; Boehringer Ingelheim; Valeant Pharma
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • Novartis Pharma AG
Research Support, Government Entities:
  • MeFoPa, EU, 241791, PI, 2010-2013; ERA-Net Neuron, BMBF, 01EW0908, PI, 2009-2012; NGFNplus, BMBF, 01GS08134, PI, 2008-2011
Research Support, Academic Entities:
  • HelMA, Helmholtz Association, PI, 2008-2011
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Demetrius Maraganore, MD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • Method to treat Parkinson’s disease; method to predict Parkinson’s disease; patents both pending.
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • Alynylam Pharmaceuticals Inc and Medtronic Inc, grant to study the genetic association of alpha synuclein gene variations with motor and cognitive outcomes in Parkinson’s disease.
Research Support, Government Entities:
  • NIH grant ES10751 (active)
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • Alnylam Pharmaceuticals, 2009
Royalty Payments, Technology or Inventions:
  • Alynlam Pharmaceutcials, method to treat Parkinson disease
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
and Rejko Krüger, MD
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • speaker’s honoraria and/or travel grants from UCB Pharma, Cephalon, Abbott Pharma, Takeda Pharma, TEVA Pharma and Medtronic
Editorial Boards:
  • European Journal of Clinical Investigations, associate editor, since 2009 Journal of Neural Transmission, associate editor, since 2009 BMC Neurology, associate editor, since 2009
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • German Research Council [DFG; KR2119/3-2, KR2119/8-1], the Federal Ministry for Education and Research [BMBF, NGFNplus; 01GS08134], The Fritz Thyssen Foundation, The Michael J Fox Foundation
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
, On behalf of the GEO-PD Consortium
From the Department for Neurodegenerative Diseases (M.S., T.G., R.K.), Hertie Institute for Clinical Brain Research, University of Tübingen, and DZNE, German Centre for Neurodegenerative Diseases, Tübingen, Germany; Stanford Prevention Research Center (J.P.A.I.), Department of Medicine and Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA; Department of Neurology (J.O.A.), St Olavs Hospital and NTNU Trondheim, Trondheim, Norway; Institute of Neurological Sciences (G. Annesi, A.Q.), National Research Council, Mangone (CS), Italy; INSERM, UMR_S975 (A.B., S.L.), Université Pierre et Marie Curie-Paris, CNRS, UMR 7225, AP-HP, Pitié-Salpêtrière Hospital, Paris, France; Department of Genetics and Cytogenetics (A.B.), Pitié-Salpêtrière Hospital, Paris, France; Neurodegenerative Brain Diseases Group (C.V.B., D.C., J.T.), Department of Molecular Genetics, VIB, Antwerp; Institute Born-Bunge (C.V.B., D.C., J.T.), University of Antwerp, Antwerp, Belgium; Neuropsychiatric Genetics Group (L.B., C.M.L.), Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany; General Hospital of Syros (M.B.), Syros; 10. “Hygeia” Hospital (M.B.), Clinic of Neurodegenerative Disorders, Athens; 2nd Neurology Clinic (M.B., L.S.), University of Athens, “Attikon” Hospital, Athens, Greece; Department of Neurology (D.C.), Antwerp University Hospital, Antwerp, Belgium; School of Clinical and Experimental Medicine (C.C., K.E.M.), College of Medical and Dental Sciences, University of Birmingham, and City Hospital, Birmingham, UK; Centre for Biomedicine (M. Facheris, A.A.H., P.P.P., I.P.), EURAC Bolzano, Bolzano, Italy; Department of Medical Genetics (M. Farrer, C.V.-G.), University of British Columbia, Vancouver, Canada; Cyclotron Research Centre (G.G.), Department of Neurology, University of Liège, Liège, Belgium; Department of Neurology (S.G., G. Auburger), Goethe University, Frankfurt am Main, Germany; Department of Neurology (G.M.H., G.X.), Faculty of Medicine, University of Thessaly and Institute of Biomedical Research and Technology, CERETETH, Larissa, Greece; Department of Neurology (N.H., H.T.), Juntendo University School of Medicine, Tokyo, Japan; Department of Neurology (B.J., S.S.P.), Seoul National University Hospital, Seoul, South Korea; Department of Neurology (C.M.L.), Johannes Gutenberg University, Mainz, Germany; Department of Neurology (J.-J.L., K.-C.Y.), Chushang Show-Chwan Hospital, Nantou and Chung-Shan Medical University Hospital, Taichung, Taiwan; The Dublin Neurological Institute at the Mater Misericordiae University Hospital (T.L.), and Conway Institute, University College Dublin, Ireland; Helmholtz Zentrum München (P.L.), German Research Centre for Environmental Health (Gmbh), Neuherberg, Germany; Movement Disorders Centre (A.E.L.), Toronto Western Hospital, University of Toronto, and Edmond J Safra Program Parkinson's Disease, Toronto, Canada; Clinical Neurology Research Centre (V.M.), Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong; Department of Neurology (B.J.-M., G.O.), Medical University of Silesia, Katowice, Poland; Eskitis Institute for Cell and Molecular Therapies (G.D.M.), Griffith University, Australia; Neurosciences Department (K.E.M., J.D.S.), Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R.), Department of Medicine, University of Toronto, Toronto, Canada; Departments of Neuroscience (O.A.R.) and Neurology (R.J.U., Z.W.), Mayo Clinic, Jacksonville, FL; Divisions of Basic Neurosciences & Cell Biology (L. Stefanis), Biomedical Research Foundation of Academy of Athens, Athens, Greece; Division of Neurology/Molecular Brain Science (W.S., T.T.), Kobe University Graduate School of Medicine, Kobe, Japan; University of Queensland Centre for Clinical Research (P.A.S.), Herston, Australia; Department of Neurology (E.-K.T., Y.Z.), Singapore General Hospital, National Neuroscience Institute, Singapore; Department of Medical Epidemiology and Biostatistics and Department of Clinical Neuroscience (K.W.), Karolinska Institutet, Stockholm, Sweden; and Department of Neurology (D.M.), NorthShore University Health System, Chicago, IL.
R.S Boyle, MD
Princess Alexandra Hospital, Brisbane , Site Investigator
A Sellbach, MD
Princess Alexandra Hospital, Brisbane, Site Investigator
J.D. O'Sullivan, MD
Royal Brisbane and Women's Hospital Brisbane, Site Investigator
G.T. Sutherland, PhD
Eskitis Institute for Cell and Molecular Therapies, Griffith University, Nathan, QLD, Site Investigator
G.A Siebert, MD
Eskitis Institute for Cell and Molecular Therapies, Griffith University, Nathan, QLD, Site Investigator
N.N.W Dissanayaka, MD
Eskitis Institute for Cell and Molecular Therapies, Griffith University, Nathan, QLD,Site Investigator
Christine Van Broeckhoven, PhD, DSc
Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB; and Laboratory of Neurogenetics, Institute Born-Bunge; and University of Antwerp, Antwerpen, Site Investigator
Jessie Theuns, PhD
Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB; and Laboratory of Neurogenetics, Institute Born-Bunge, and University of Antwerp, Antwerpen, Site Investiagtor
David Crosiers, MD
Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB; and Laboratory of Neurobiology, Institute Born-Bunge; and University of Antwerp; and Division of Neurology, University Hospital Antwerp, Antwerpen, Site Investigator
Barbara Pickut, MD
Memory Clinic and Division of Neurology, ZNA Middelheim, Antwerpen; and Division of Neurology, University Hospital Antwerp, Antwerpen, Site Investigator
Sebastiaan Engelborghs, MD, PhD
Laboratory of Neurochemistry and Behavior, Institute Born-Bunge; and University of Antwerp; and Memory Clinic and Division of Neurology, ZNA Middelheim, Antwerpen, Site Investigator
Bram Meeus, PhD
Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB; and Laboratory of Neurogenetics, Institute Born-Bunge; and University of Antwerp, Antwerpen, Site Investigator
Peter P. De Deyn, MD, PhD
Laboratory of Neurochemistry and Behavior, Institute Born-Bunge; and University of Antwerp; and Memory Clinic and Division of Neurology, ZNA Middelheim, Antwerpen, Site Investigator
Patrick Cras, MD, PhD
Laboratory of Neurobiology, Institute Born-Bunge; and University of Antwerp; and Division of Neurology, University Hospital Antwerp, Antwerpen; Site Investigator
Ekaterina Rogaeva, PhD
Tanz Centre for Research in Neurodegenerative Diseases, Department of Medicine, Division of Neurology, University of Toronto, ON, Canada, Site Investiagtor
Anthony E Lang, MD
Movement Disorders Centre, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, Site Investigator
Y Agid, MD
Inserm U708, Paris, From the French Parkinson's Disease Genetics Study Group, Site Investigator
M Anheim, MD
Inserm U708, Paris, From the French Parkinson's Disease Genetics Study Group, Site Investigator
A-M Bonnet, MD
Inserm U708, Paris, From the French Parkinson's Disease Genetics Study Group, Site Investigator
M Borg, MD
Inserm U708, Paris, From the French Parkinson's Disease Genetics Study Group, Site Investigator
A Brice, MD
Inserm U708, Paris, From the French Parkinson's Disease Genetics Study Group, Site Investigator
E Broussolle, MD
Inserm U708 E , Paris, From the French Parkinson's Disease Genetics Study Group, Site Investigator
JC Corvol, MD
Inserm U708 JC , Paris, From the French Parkinson's Disease Genetics Study Group, Site Investigator
P Damier, MD
Inserm U708, Paris, From the French Parkinson's Disease Genetics Study Group, Site Investigator
A Destée, MD
Inserm U708, Paris, From the French Parkinson's Disease Genetics Study Group, Site Investigator
A Dürr, MD
Inserm U708, Paris, From the French Parkinson's Disease Genetics Study Group, Site Investigator
F Durif, MD
Inserm U708, Paris, From the French Parkinson's Disease Genetics Study Group, Site Investigator
S Lesage, PhD
Inserm U708, Paris, From the French Parkinson's Disease Genetics Study Group, Site Investigator
E Lohmann, MD
Inserm U708, Paris, From the French Parkinson's Disease Genetics Study Group, Site Investigator
P Pollak, MD
Inserm U708, Paris, From the French Parkinson's Disease Genetics Study Group, Site Investigator
O Rascol, MD
Inserm U708, Paris, From the French Parkinson's Disease Genetics Study Group, Site Investigator
F Tison, MD
Inserm U708, Paris, From the French Parkinson's Disease Genetics Study Group, Site Investigator
C Tranchant, MD
Inserm U708, Paris, From the French Parkinson's Disease Genetics Study Group, Site Investigator
F Viallet, MD
Inserm U708, Paris, From the French Parkinson's Disease Genetics Study Group, Site Investigator
M Vidailhet, MD
Inserm U708, Paris, From the French Parkinson's Disease Genetics Study Group, Site Investigator
Christophe Tzourio, MD
Inserm U708, Paris, From the French Parkinson's Disease Genetics Study Group, Site Investigator
Philippe Amouyel, MD
Inserm U744, Lille, Site Investigator
Marie-Anne Loriot, MD
Inserm UMRS775, Paris, Site Investigator
Eugénie Mutez, MD
Inserm UMR837, Service de Neurologie et de Pathologie du Mouvement CHRU de Lille, Univ Lille Nord de France, Site Investigator
Aurélie Duflot, MD
UMR837 Inserm-Univ Lille 2, CHRU de Lille, Site Investigator
Jean-Philippe Legendre, MD
Service de Neurologie et Pathologie du Mouvement, Clinique de Neurologie du CHU de Lille, Site Investigator
Nawal Waucquier, MD
Service de Neurologie et Pathologie du Mouvement, Clinique de Neurologie du CHU de Lille, Site Investigator
Thomas Gasser, MD
Department of Neurology, University Hospital Tuebingen, Site Investigator
Olaf Riess, MD
Department of Neurology, University Hospital Tuebingen, Site Investigator
Daniela Berg, MD
Department of Neurology, University Hospital Tuebingen, Site Investigator
Claudia Schulte, MSc
Department of Neurology, University Hospital Tuebingen, Site Investigator
Christine Klein, MD
Section of Clinical and Molecular Neurogenetics at the Department of Neurology, University of Lübeck, Site Investigator
Ana Djarmati, PhD
Department of Neurology, University of Lübeck, Site Investigator
Johann Hagenah, MD
Department of Neurology, University of Lübeck, Site Investigator
Katja Lohmann, PhD
Section of Clinical and Molecular Neurogenetics at the Department of Neurology, University of Lübeck, Site Investigator
Georg Auburger, MD
Department of Neurology, Goethe University Frankfurt am Main, Germany, Site Investigator
Rüdiger Hilker, MD
Department of Neurology, Goethe University Frankfurt am Main, Germany, Site Investigator
Simone van de Loo, MD
Department of Neurology, Goethe University Frankfurt am Main, Germany, Site Investigator
Efthimios Dardiotis, MD
Department of Neurology, Faculty of Medicine, University of Thessaly and Institute of Biomedical Research & Technology, CERETETH, Larissa; Site Investigator
Vaia Tsimourtou, MD
Department of Neurology, Faculty of Medicine, University of Thessaly, Larissa, Site Investigator
Styliani Ralli, MD
Department of Neurology, Faculty of Medicine, University of Thessaly, Larissa, Site Investigator
Persa Kountra, MD
Department of Neurology, Faculty of Medicine, University of Thessaly, Larissa, Site Investigator
Gianna Patramani, MD
Department of Neurology, Faculty of Medicine, University of Thessaly, Larissa, Site Investigator
Cristina Vogiatzi, MD
Department of Neurology, Faculty of Medicine, University of Thessaly, Larissa, Site Investigator
Nobutaka Hattori, MD, PhD
Department of Neurology, Juntendo University School of Medicine, Tokyo, Site Investigator
Hiroyuki Tomiyama, MD, PhD
Department of Neurology, Juntendo University School of Medicine, Tokyo, Site Investigator
Manabu Funayama, PhD
Department of Neurology, and Research Institute for Diseases of Old Age, Graduate School of Medicine, Juntendo University, Tokyo, Site Investigator
Hiroyo Yoshino, BS
Research Institute for Diseases of Old Age, Graduate School of Medicine, Juntendo University, Tokyo, Site Investigator
Yuanzhe Li, MD, PhD
Department of Neurology, Juntendo University School of Medicine, Tokyo, Site Investigator
Yoko Imamichi, MD
Department of Neurology, Juntendo University School of Medicine, Tokyo, Site Investigator
Tatsushi Toda, MD
Division of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Japan, Site Investigator
Wataru Satake, MD, PhD
Division of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Japan, Site Investigator
Tim Lynch, MD
The Dublin Neurological Institute at the Mater Misericordiae University Hospital, Clinical Investigator at the Conway Institute, University College Dublin, Ireland, Site Investigator
J. Mark Gibson, MD
Department of Neurology, Royal Victoria Hospital, Belfast, Ireland, Site Investigator
Enza Maria Valente, MD, PhD
IRCCS, Casa Sollievo della Sofferenza Hospital, Mendel Institute, San Giovanni Rotondo, Site Investigator
Alessandro Ferraris, MD
IRCCS, Casa Sollievo della Sofferenza Hospital, Mendel Institute, San Giovanni Rotondo, Site Investigator
Bruno Dallapiccola, MD
Mendel Institute, Casa Sollievo della Sofferenza Hospital, Rome, Site Investigator
Tamara Ialongo, MD, PhD
Institute of Neurology, Catholic University, Rome, Site Investigator
Laura Brighina, MD, PhD
Department of Neurology, Ospedale San Gerarado, Monza, Italy, Site Investigator
Barbara Corradi, PhD
Department of Paediatrics, University of Milano-Bicocca, Monza, Site Investigator
Roberto Piolti, MD
Department of Neurology, Ospedale San Gerardo, Monza, Italy, Site Investigator
Patrizia Tarantino, PhD
Institute of Neurological Sciences,National Research Council, Site Investigator
Ferdinanda Annesi, PhD
Institute of Neurological Sciences, National Research Council, Site Investigator
Beom S. Jeon, MD, PhD
Department of Neurology, Seoul National University Hospital, Site Investigator
Sung-Sup Park, MD, PhD
Department of Laboratory Medicine, Seoul National University Hospital, Site Investigator
J Aasly, MD
Department of Neurology, University of Trondheim, Norway, Site Investigator
Grzegorz Opala, MD, PhD
Department of Neurology, Aging, Degenerative and Cerebrovascular Disorders, Medical University of Silesia, Katowice; Site Investigator
Barbara Jasinska-Myga, MD, PhD
Department of Neurology, Aging, Degenerative and Cerebrovascular Disorders, Medical University of Silesia, Katowice, Site Investigator
Gabriela Klodowska-Duda, MD, PhD
Department of Neurology, Aging, Degenerative and Cerebrovascular Disorders, Medical University of Silesia, Katowice, Site Investigator
Magdalena Boczarska-Jedynak, MD, PhD
Department of Neurology, Aging, Degenerative and Cerebrovascular Disorders, Medical University of Silesia, Katowice, Site Investigator
Eng King Tan, MD, PhD
National Medical and Biomedical Research Councils, and the Duke-NUS Graduate Medical School, Singapore Millenium Foundation, Site Investigator
Andrea Carmine Belin, PhD
Department of Neuroscience, KarolinskaInstitutet, Stockholm, Site Investigator
Lars Olson, MD
Department of Neuroscience, KarolinskaInstitutet, Stockholm, Site Investigator
Dagmar Galter, PhD
Department of Neuroscience, KarolinskaInstitutet, Stockholm; Site Investigator
Marie Westerlund, PhD
Department of Neuroscience, KarolinskaInstitutet, Stockholm, Site Investigator
Olof Sydow, PhD
Department of Clinical Neuroscience, Karolinska University Hospital, Stockholm; Site Investigator
Christer Nilsson, MD, PhD
Department of Geriatric Psychiatry, Lund University; Site Investigator
Andreas Puschmann, MD
Department of Neurology, Lund University Hospital, Department of Geriatric Psychiatry, Lund University, Site Investigator
JJ Lin, MD
Department of Neurology, Cushang Show-Chwan Hospital, Taiwan, Site Investigator
Demetrius M. Maraganore, MD
Department of Neurology, NorthShore Health Systems, Chicago, IL, Site Investigator
J, Eric Ahlskog, PhD, MD
Department of Neurology, Mayo Clinic, Rochester, MN, USA, Site Investigator
Mariza de Andrade, PhD
Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA, Site Investigator
Timothy G. Lesnick, MS
Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA, Site Investigator
Walter A. Rocca, MD, MPH
Departments of Neurology and Health Sciences Research, Mayo Clinic, Rochester, MN, USA, Site Investigator
Harvey Checkoway, PhD
Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, Site Investigator
Owen A Ross, PhD
Division of Neuroscience, Mayo Clinic, Jacksonville, USA, Site Investigator
Zbigniew K. Wszolek, MD
Department of Neurology, Mayo Clinic, Jacksonville, FL, Site Investigator
Ryan J. Uitti, MD
Department of Neurology, Mayo Clinic, Jacksonville, FL, Site Investigator
corresponding authorCorresponding author.
Correspondence & reprint requests to Dr. Sharma: manu.sharma/at/uni-tuebingen.de
Received July 13, 2011; Accepted January 25, 2012.
Objective:
Eleven genetic loci have reached genome-wide significance in a recent meta-analysis of genome-wide association studies in Parkinson disease (PD) based on populations of Caucasian descent. The extent to which these genetic effects are consistent across different populations is unknown.
Methods:
Investigators from the Genetic Epidemiology of Parkinson's Disease Consortium were invited to participate in the study. A total of 11 SNPs were genotyped in 8,750 cases and 8,955 controls. Fixed as well as random effects models were used to provide the summary risk estimates for these variants. We evaluated between-study heterogeneity and heterogeneity between populations of different ancestry.
Results:
In the overall analysis, single nucleotide polymorphisms (SNPs) in 9 loci showed significant associations with protective per-allele odds ratios of 0.78–0.87 (LAMP3, BST1, and MAPT) and susceptibility per-allele odds ratios of 1.14–1.43 (STK39, GAK, SNCA, LRRK2, SYT11, and HIP1R). For 5 of the 9 replicated SNPs there was nominally significant between-site heterogeneity in the effect sizes (I2 estimates ranged from 39% to 48%). Subgroup analysis by ethnicity showed significantly stronger effects for the BST1 (rs11724635) in Asian vs Caucasian populations and similar effects for SNCA, LRRK2, LAMP3, HIP1R, and STK39 in Asian and Caucasian populations, while MAPT rs2942168 and SYT11 rs34372695 were monomorphic in the Asian population, highlighting the role of population-specific heterogeneity in PD.
Conclusion:
Our study allows insight to understand the distribution of newly identified genetic factors contributing to PD and shows that large-scale evaluation in diverse populations is important to understand the role of population-specific heterogeneity. Neurology® 2012;79:659–667
Genome-wide association studies (GWAS) have provided tangible gains in understanding the genetic architecture of complex diseases,1,2 including Parkinson disease (PD).3 Several GWAS have been conducted in PD in Caucasian populations and only 1 in the Asian population.311 Consistent and reproducible association signals were confirmed in α-synuclein (SNCA), leucine-rich repeat kinase 2 (LRRK2), and microtubule-associated protein tau (MAPT), thus underscoring the importance of these 3 genes in the pathophysiology of the common sporadic forms of PD.310,12 In addition to that, different studies have provided some evidence for an association for BST1, GAK, and HLA-DRB5 with PD.69,13
A recently published GWAS meta-analysis in PD increased the number of identified PD genetic loci to 11.14 This study reported significant between-study heterogeneity for some of the 11 genetic loci14 even though data were restricted to Caucasian descent populations.
It is important to establish whether the 11 genetic loci that have been postulated to be associated with PD are replicated when tested with direct genotyping in a larger spectrum of diverse populations. The consistency or lack thereof of the genetic effects of these genetic variants across different populations may help to determine whether they represent genuine loci for PD susceptibility and whether they can be used for risk prediction across these diverse populations.15 To gain further insight into genetic factors contributing to PD across different populations and define the implications of between-population heterogeneity, we performed a large-scale replication study within the GEO-PD consortium.
Consortium.
Investigators from the Genetic Epidemiology of PD (GEO-PD) Consortium were invited to participate in this study. A total of 21 sites representing 19 countries from 4 continents agreed to contribute DNA samples and clinical data for a total of 17,705 individuals (8,750 cases and 8,955 controls). Healthy individuals matched for age and gender served as controls. They underwent neurologic examination and were excluded from the study whenever there was clinical evidence for any extrapyramidal disorder.
Genotyping.
We selected 1 SNP per each gene locus, exactly as they were proposed by the recently published GWAS meta-analysis.14 Genotyping was performed by a central genotyping core (Department of Human Genetics, Helmholtz Zentrum, Munich). Each site provided 100–200 ng of DNA to the laboratory core. In total 11 SNPs located in and around the genes encoding SYT11, ACMSD, STK39, LAMP3, GAK, BST1, SNCA, HLA-DRB5, LRRK2, HIP1R, and MAPT were genotyped. The genotyping core was blinded to case-control status of each site. Genotyping was performed using a matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry on a MassArray system (Sequenom, San Diego, CA). Cleaned extension products were analyzed by a mass spectrometer (Bruker Daltronik, USA) and peaks were identified using the MassArray Typer 4.0.2.5 software (Sequenom). Assays were designed by the AssayDesigner software 4.0 (Sequenom) with the default parameters for the iPLEX Gold chemistry and the Human GenoTyping Tools ProxSNP and PreXTEND (Sequenom). All variants were genotyped in 1 multiplex assay. An experienced investigator blinded to case or control status of the samples visually checked genotype clustering. The average call rate of the variants was >97%.
In order to further enrich the samples of Asian ancestry populations, we also included GWAS data from a Japanese population (988 cases, 2,521 controls).6 We used r2 threshold of 0.8–1.0 to select proxy SNPs from the Japanese GWAS. Using this threshold, we were able to capture only 3 SNPs from BST1, SNCA, and LRRK2 genes.
Standard protocol approvals, registrations, and patient consents.
The local Ethics Committee approved the study. All participants signed an informed consent.
Analysis.
An exact test was used to assess whether the genotype distributions for each SNP deviated from Hardy-Weinberg equilibrium (HWE) among controls; each site was tested separately and deviation from HWE was considered significant at <0.01. We excluded data from sites where the missing rate was >5%. For our analysis, we adhered to the same allele coding as in the previous GWAS meta-analysis.14
For consistency effect estimates based on minor vs major allele contrast were computed. We used an additive model adjusted for age and gender to obtain effect estimates. Results were then synthesized using fixed and random effects models. Fixed effect models assume that the genetic effect is the same in populations from different sites and that observed differences are due to chance alone. For associations showing between-study heterogeneity, fixed effect estimates yield narrower confidence intervals (CIs) and smaller p values as compared to random effects models, which incorporate between-study heterogeneity.1618 Fixed effects analysis tests the null hypothesis of no association in all studied populations that are analyzed. Routinely, this assumption is used in GWAS settings to increase the power of meta-analysis to detect associations that may exist in some (at least 1) population. However, in presence of heterogeneity the effects may differ substantially in different populations and not all populations may show a genetic effect for the variant of interest. Random effects models allow the genetic effects might be different due to genuine heterogeneity that may exist across different sites. Random effects calculations take into account the estimated between-study heterogeneity. We used the inverse variance method for fixed effects models. Cochran Q test of homogeneity and the I2 metric were used to evaluate the between-site heterogeneity. The Q statistics follows χ2-based distribution with k −1 degrees of freedom (k = number of studies). I2 is estimated by the ratio (Q-df)/Q, where df is degrees of freedom. The I2 metric ranges from 0% to 100% and measures the proportion of variability that is beyond chance. Typically estimates of I2 <25% are considered to reflect little or no heterogeneity, 25%–50% moderate heterogeneity, 50%–75% large heterogeneity, and >75% very large heterogeneity. It should be acknowledged that I2 can have large uncertainty in its estimation especially for variants with low minor allele frequency. Therefore, we also estimated the 95% CI of I2.17
The overall main analysis considered all sites and populations irrespective of ancestry. Then, we separately analyzed Caucasian and Asian sites and we compared the genetic effects in these 2 major ancestry groups.
The SNPs evaluated in the recently published GWAS meta-analysis are common with minor allele frequencies varying from 13% to 46%,14 except for SNP, rs34372695 (SYT11) where the minor allele frequency is 2%. Therefore, based on minor allele frequency and effect estimates obtained in the GWAS meta-analysis,14 power calculations showed that our study would have at least 99% power to detect an allele-based odds ratio (OR) of 1.2 for minor allele frequencies of 10% or higher for α = 0.05. Based on genome-wide significance level (α = 5 × 10−8), our study would have 43% power to detect an allele-based OR of 1.2 for minor allele frequency of 10%, but it would be 99% for same minor allele frequency and on OR of 1.4. Power would be only 69% for a minor allele frequency of 2% and OR of 1.2, but it would be 99% for the same minor allele frequency of 2% and an OR of 1.5.
Meta-analyses were performed using STATA 9.0 (Stata Corp., College Station, TX) and Review Manager 4.2.7. p Values are 2-tailed.
Characteristics of sites and overall database.
Twenty-one sites contributed a total of 8,750 cases and 8,955 controls. Characteristics of all participating sites are shown in table 1. Most sites contributed participants of Caucasian ancestry (n = 16); 5 sites (counting also the GWAS performed in the Japanese population6) included participants of Asian ancestry. We excluded 1 site with 114 cases and 67 controls from the analysis due to a plate layout error. The median age at onset was 59 years and median age at examination was 67 years.
Table 1
Table 1
Description of datasets contributed by each study site
We observed that for one site, effect estimates for all SNPs were “inverse” as compared to other Caucasian sites. Allele flipping for one particular site in the same Caucasian descent might reflect error in sampling ascertainment and is unlikely to reflect genuine effects.19 This site (n = 181) was therefore excluded from further analyses. Overall, genotype call rates were >97%. The genotype distribution for each SNP in the controls of each site showed no departure from HWE, except for rs6599388 (GAK) in samples from 4 Asian sites. We therefore excluded this SNP (rs6599388) from analyses in the Asian population.
Overall data synthesis.
We observed consistent and reproducible associations for SNCA, LRRK2, MAPT, BST1, GAK, STK39, SYT11, LAMP3, and HIP1R loci but not for ACMSD (rs10928513) or HLA-DRB5 (rs3129882) where the per-allele OR was very close to the null (1.02 and 0.95, respectively) and statistically nonsignificant (table 2). Thus we provide unequivocal support for the involvement of these newly identified genetic loci in the pathogenesis of PD.
Table 2
Table 2
Overall analysis irrespective of ethnicity and influence of between-study heterogeneity
Summary effect estimates were generally comparable with the previous GWAS meta-analysis results (table 2), although effect estimates in this study were stronger for STK39 and somewhat weaker for LRRK2 compared to the previous GWAS meta-analysis.14 Exclusion of 1,625 samples that overlap with the previously published GWAS did not change any of the estimates (table e-1 on the Neurology® Web site at www.neurology.org). The protective per-allele OR ranged from 0.78 to 0.87 (LAMP3, BST1, and MAPT) and the susceptibility per-allele OR ranged from 1.14 to 1.43 (STK39, GAK, SNCA, LRRK2, SYT11, and HIP1R). Cochran Q statistics were nominally significant for STK39, LAMP3, BST1, and SNCA with I2 estimates ranging from 39% to 48%. The heterogeneity reflected primarily differences in the magnitude of the effect sizes across different sizes, while the direction of the effect was consistent in all sites, with rare exceptions.
Analysis including only Caucasian sites.
Restricting the analysis to Caucasian sites only resulted in per-allele ORs that ranged from 0.78 to 0.90 for the 3 replicated protective loci (BST1, LAMP3, and MAPT) and from 1.14 to 1.43 for the 6 replicated susceptibility loci (STK39, GAK, SNCA, LRRK2, SYT11, and HIP1R), while ACMSD and HLA-DRB5 still had no significant effect (table 3 and figure e-1).
Table 3
Table 3
Caucasian specific effect estimates and influence of between-study heterogeneity
Summary effect estimates were generally comparable to those of the previous GWAS meta-analysis,14 except for modest differences in STK39 and LRRK2 effect sizes, as noted above also for the overall analysis. There was nominally significant heterogeneity only for SNCA and LAMP3 (I2 estimates 51% and 46%, respectively), but this reflected primarily differences in the magnitude of the effect size estimates rather than direction of effects across sites (figure e-1).
Analysis including only Asian sites.
In the Asian series, not only the SYT11 SNP, but also the ACMSD and MAPT SNPs were monomorphic (table e-2). Summary effect estimates for the remaining SNPs are shown in table 4. We again observed consistent nominally significant evidence of association for all loci except for STK39 (which still had an effect size estimate consistent with what was seen in the overall analysis) and HLA-DRB5 (which had a point estimate very close to the null), which still had an effect size estimate consistent with what was seen in the overall analysis. Results were generally consistent across sites, with the exception of STK39 that showed very large heterogeneity (I2 = 73%) (figure e-2).
Table 4
Table 4
Asian specific effects and influence of between-study heterogeneity
Comparison of effect size estimates.
Five gene loci (HIP1R, LAMP3, LRRK2, SNCA, and STK39) where both Caucasians and Asian populations were represented showed no difference in effect size estimates that were different beyond chance (figure 1). Conversely for BST1, the effects were different beyond chance for Asian and Caucasian populations with stronger genetic effects in the former.
Figure 1
Figure 1
Forest plot showing the comparison of effect of each single nucleotide polymorphism (SNP) in Caucasian and Asian population
We performed a large-scale evaluation to assess the role of recently discovered genetic risk variants in the pathogenesis of PD in different populations. Our study confirms 9 of the 11 postulated susceptibility SNPs for PD. The confirmed SNPs include the previously well documented LRRK2, SNCA, BST1, GAK, and MAPT associations,3,68,10,20 and 4 of the 5 more recently proposed associations in STK39, SYT11, LAMP3, and HIP1R SNPs that might act as risk factors for PD. Conversely, we were unable to confirm the association between PD risk and SNPs rs10928513, rs3129882 in ACMSD and HLA-DRB5, respectively. Three SNPs were monomorphic in the Asian datasets.
The recently proposed ACMSD locus is likely to have represented a spurious association. The OR is very close to the null and 95% CI also excludes an OR larger than 1.08. Of note, even in GWAS meta-analysis, the OR estimate was only 1.07 in the replication phase, as compared with 1.38 in the discovery phase. Our results are in agreement with a recently published study.21 This finding suggests that large-scale replication with direct genotyping is useful even for SNPs that pass conventional genome-wide significance thresholds. It is possible that with the use of the more extended imputation platforms using the 1,000 Genomes Project, the number of comparisons made is larger than what was done in the past with more limited imputation platforms and this may thus require more stringent levels of significance to claim genome-wide significance.
As observed in a recently published study,9 the frequency of the HLA-DRB5 SNP, rs3129882, varies considerably even within seemingly homogenous Caucasian populations; the frequency of risk allele is low in subjects of Northern European descent as compared to subjects from Southern European descent. Therefore, the observed lack of association for the HLA-DRB5-specific SNP rs3129882 should be interpreted with caution. Moreover, directionality as well as the magnitude of effect estimates obtained in our study for the HLA-DRB5 locus specific SNP are comparable with previously published studies.9,22
Our study shed light on the role of heterogeneity in PD genetics. Detection of heterogeneity could provide new insight to understand the genetic architecture of the disease.17,23,24 A number of factors can be attributed to the observed heterogeneity. First, clinically overlapping pathologies may lead to heterogeneity. Indeed the presence of distinct subgroups of patients during early clinical stages of PD could contribute to clinical heterogeneity.25 Therefore, it is worth it to consider that genetic variants may exert different pathologic processes that eventually lead to complex clinical phenotypes.26 For example, it has been shown that multiplications of SNCA gene lead to clinical phenotype, which clinically overlap with multiple system atrophy (MSA).27 Moreover, SNPs in the 3′UTR of SNCA were shown to be associated with PD as well as MSA.3,68,28 The most significant SNPs in both diseases clustered around 3[double less-than sign]UTR of SNCA; SNP rs11931074, that was significantly associated with MSA in contrast to rs356219 in the PD meta-analysis.14,28 The r2 between these 2 markers was only 0.16 in the Caucasian population. These 2 distinct signals in different yet overlapping pathologies therefore might reflect one cause of genetic heterogeneity. Second, heterogeneity might reflect that different tagging polymorphisms were used in previously published GWAS. Of note, a recently published GWAS from United Kingdom, France, and Netherlands provided weak (as they did not surpass genome-wide significant threshold) yet consistent association signals for the BST1 and GAK gene.7,8,13 This probably reflects that the investigated markers were not causal variants but in linkage disequilibrium with a potential causal variant across different studies.
Our study helps to understand the role of population-specific heterogeneity in PD risk loci. Some risk variants exist only in populations of specific ancestry. For example, it is known that an ancient inversion (~900 kb) in the MAPT region occurred, which led to the formation of 2 nonrecombining haplotypes, H1 and H2.29 The H2 haplotype is absent in East Asian populations as has been shown also by a recently published Asian GWAS that revealed no association for the MAPT locus.6 This is in contrast to previously published candidate gene studies and GWAS in Caucasian populations that have shown consistent association with the MAPT locus.3,7,8,13
Some other variants may have a different magnitude of effect in populations of different ancestry. In our data, this is well exemplified by BST1, where the OR was significantly larger in populations of Asian than those of Caucasian ancestry. Conversely, we found that associations in 5 loci (SNCA, LRRK2, LAMP3, HIP1R, and STK39) had similar effects in these 2 ancestries.
The consistency or diversity of effect sizes in identified associations may reflect different patterns of linkage disequilibrium in these loci in diverse populations. It may also reflect differences in the susceptibility to develop PD and perhaps also differences in age at onset in different ancestry groups. The diversity in the magnitude of effects is important to take into account when considering the use of such information for personalized risk modeling.30 Therefore caution should be used in extrapolating risks across different populations.
Our study provides strong and independent support for the role of 9 loci in the pathogenesis of PD in different populations. The detection and documentation of heterogeneity across different populations is useful in understanding the genetic architecture of this complex disease and in properly framing our ability to use this information in different clinical populations.
Supplementary Material
Data Supplement
Coinvestigators
Accompanying Editorial
GLOSSARY
CIconfidence interval
GEO-PDGenetic Epidemiology of Parkinson's Disease
GWASgenome-wide association studies
HWEHardy-Weinberg equilibrium
MALDI-TOFmatrix-assisted laser desorption/ionization time-of-flight
MSAmultiple system atrophy
ORodds ratio
PDParkinson disease
SNPsingle nucleotide polymorphism

Footnotes
Editorial, page 619
Supplemental data at www.neurology.org
Coinvestigators are listed on the Neurology® Web site at www.neurology.org.
AUTHOR CONTRIBUTIONS
Manu Sharma, PhD: Dr. Sharma designed the study, performed the statistical analysis, and wrote the manuscript. John P.A. Ioannidis, MD: Dr. Ioannidis performed the statistical analysis and participated in writing of the manuscript. Jan O Aasly, MD: Dr. Aasly contributed samples and collected phenotypic data. Grazia Annesi, MD: Dr. Annesi contributed samples and collected phenotypic data. Alexis Brice, MD: Dr. Brice contributed samples and collected phenotypic data. Christine Van Broeckhoven, PhD: Dr. Van Broeckhoven contributed samples and collected phenotypic data. Lars Bertram, MD: Dr. Bertram participated in writing the manuscript. Maria Bozi, MD: Dr. Bozi contributed samples and collected phenotypic data. David Crosiers, MD: Dr. Crosiers contributed samples and collected phenotypic data. Carl Clarke, MD: Dr. Clarke contributed samples and collected phenotypic data. Maurizzio Facheris, MD: Dr. Facheris contributed samples and collected phenotypic data. Matthew Farrer, PhD: Dr. Farrer contributed samples and collected phenotypic data. Gaetan Garraux, MD, PhD: Dr. Garraux contributed samples and collected phenotypic data. Suzana Gispert, PhD: Dr. Gispert contributed samples and collected phenotypic data. Georg Auburger, MD: Dr. Auburger contributed samples and collected phenotypic data. Carles Vilariño-Güell, PhD: Dr. Vilariño-Güell contributed samples and collected phenotypic data. Georgios M. Hadjigeorgiou, MD: Dr. Hadjigeorgiou contributed samples and collected phenotypic data. Andrew Hicks, PhD: Dr. Hicks contributed samples and collected phenotypic data. Nobutaka Hattori, MD: Dr. Hattori contributed samples and collected phenotypic data. Beom Jeon, MD: Dr. Jeon contributed samples and collected phenotypic data. Suzanne Lesage, MD: Dr. Lesage contributed samples and collected phenotypic data. Christina M Lill, MD: Dr. Lill participated in writing the manuscript. Juei-Jueng Lin, MD: Dr. Lin contributed samples and collected phenotypic data. Timothy Lynch, MD: Dr. Lynch contributed samples and collected phenotypic data. Peter Lichtner, PhD: Dr. Lichtner contributed samples and collected phenotypic data. Anthony E. Lang, MD: Dr. Lang contributed samples and collected phenotypic data. Vincent Mok, MD: Dr. Mok contributed samples and collected phenotypic data. Barbara Jasinska-Myga, MD, PhD: Dr. Jasinska-Myga contributed samples and collected phenotypic data. George D. Mellick, PhD: Dr. Mellick contributed samples and collected phenotypic data and critically reviewed the manuscript. Karen E Morrison, MD: Dr. Morrison contributed samples and collected phenotypic data. Grzegorz Opala, MD: Dr. Opala contributed samples and collected phenotypic data. Peter P. Pramstaller: Dr. Pramstaller contributed samples and collected phenotypic data. Irene Pichler, MD: Dr. Pichler contributed samples and collected phenotypic data. Sung Sup Park, MD: Dr. Park contributed samples and collected phenotypic data. Aldo Quattrone, MD: Dr. Quattrone contributed samples and collected phenotypic data. Ekaterina Rogaeva, PhD: Dr. Rogaeva contributed samples and collected phenotypic data and participated in writing of the manuscript. Owen A Ross, PhD: Dr. Ross contributed samples and collected phenotypic data. Leonidas Stefanis, MD: Dr. Stefanis contributed samples and collected phenotypic data. Joanne D. Stockton, PhD: Dr. Stockton contributed samples and collected phenotypic data. Wataru Satake, MD, PhD: Dr. Satake contributed samples and collected phenotypic data. Peter A. Silburn, PhD: Dr. Silburn contributed samples and collected phenotypic data. Jessie Theuns, PhD: Dr. Theuns contributed samples and collected phenotypic data. Eng-King Tan, MD: Dr. Tan contributed samples and collected phenotypic data. Tatsushi Toda, MD, PhD: Dr. Toda contributed samples and collected phenotypic data. Dr. Hiroyuki Tomiyama, MD, PhD: Dr. Tomiyama contributed samples and collected phenotypic data. Ryan J Uitti, MD: Dr. Uitti contributed samples and collected phenotypic data. Karin Wirdefeldt, MD: Dr. Wirdefeldt contributed samples and collected phenotypic data. Zbigniew Wszolek, MD: Dr. Wszolek contributed samples and collected phenotypic data. Georgios Xiromerisiou, MD: Dr. Xiromerisiou contributed samples and collected phenotypic data. Kuo-Chu Yueh, MD: Dr. Yueh contributed samples and collected phenotypic data. Yi Zhao, MD: Dr. Zhao contributed samples and collected phenotypic data. Thomas Gasser, MD: Dr. Gasser contributed samples and collected phenotypic data and participated in writing of the manuscript. Demetrius M. Maraganore, MD: Dr. Maraganore contributed samples and collected phenotypic data. Rejko Krüger, MD: Dr. Krüger contributed samples and collected phenotypic data and participated in writing of the manuscript.
DISCLOSURE
M. Sharma received funding support from Michael J Fox Foundation USA and travel grant from Movement Disorders Society. J.P.A. Ioannidis reports no disclosures. J.O. Aasly is supported by Norwegian Research Council and Reberg's Legacy. G. Annesi reports no disclosures. A. Brice receives grant support from Eranet Neuron (Co-PI), ANR Maladies Neurologiques et Psychiatriques 2008 (Co-PI), and PHRC National 2006 and 2008. C. Van Broeckhoven received funding from Research Foundation Flanders (FWO), research grant G.0085.08, co-PI; Research Foundation Flanders (FWO), Belgium, postdoctoral fellowship, PI; Agency for Innovation by Science and Technology-Flanders (IWT), research grant 080020, co-PI; Flemish Government, Belgium, Methusalem excellence grant, key personnel; Belgian Science Policy Office, Interuniversity Attraction Poles program (IUAP) P6/43, key personnel; University of Antwerp, Belgium, Special Research Fund, key personnel; Foundation for Alzheimer Research (SAO-FRMA), Belgium; research grant 09007, PI; Alzheimer's Association, USA, New Investigator Research Grant, NIRG-09-132000, PI; Belgian Parkinson Foundation, Belgium, research grant, PI. L. Bertram, M. Bozi, D. Crosiers, C. Clarke, and M. Facheris report no disclosures. M. Farrer and Mayo Foundation received royalties from H. Lundbeck A/S and Isis Pharmaceuticals. In addition, Dr. Farrer has received an honorarium for a seminar at Genzyme. G. Garraux, S. Gispert, G. Auburger, C. Vilariño-Güell, G.M. Hadjigeorgiou, and A. Hicks report no disclosures. N. Hattori has been serving as an advisory board member for Boehringer Ingelheim; as a result of attending advisory board meetings he received personal compensation. Nobutaka Hattori also has been serving as an advisory board member for FP Pharmaceutical Company by attending these advisory meetings he received personal compensation. He has been consulting with Ohtsuska Pharmaceutical Company, Kyowa Hakko Kirin Pharmaceutical Company, GlaxoSmithKline, Novartis, and Schering-Plough, and when he attended these advisory board meetings, he received personal compensation. B. Jeon has received funding for travel from GlaxoSmithKline Korea and Novartis Korea and has received research support as PI from Novartis, Boehringer Ingelheim, Ipsen Korea, the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (#A030001), ABRC (Advanced Biometric Research Center), KOSEF (Korea Science and Engineering Foundation), Seoul National University Hospital, the Mr. Chung Suk-Gyoo and Sinyang Cultural Foundation, and the Song Foundation. S. Lesage, C.M. Lill, and J.-J. Lin report no disclosures. T. Lynch has served on an advisory board for Biogen and Novartis and has received honoraria from Lundbeck, Biogen, and Boehringer-Ingelheim. P. Lichtner reports no disclosures. A.E. Lang has served as an advisor for Abbott, Allon Therapeutics, Astra Zeneca, Biovail, Boerhinger-Ingelheim, Cephalon, Ceregene, Eisai, Medtronic, Lundbeck A/S, Novartis, Merck Serono, Solvay, and Teva and received grants from Canadian Institutes of Health Research, Dystonia Medical Research Foundation, Michael J. Fox Foundation, National Parkinson Foundation, and Ontario Problem Gambling Research Centre and has served as an expert witness in cases related to the welding industry. V. Mok reports no disclosures. B. Jasinska-Myga was partially supported by the Robert and Clarice Smith Fellowship Program and the Pacific Alzheimer Research Foundation (PARF) C06-01 grant. G.D. Mellick reports no disclosures. K. E. Morrison has received grant support from Parkinson's UK, The Medical Research Council UK, the Wellcome Trust, and the Midlands Neurological Teaching and Research Fund. G. Opala was partially supported by the Robert and Clarice Smith Fellowship Program and the Pacific Alzheimer Research Foundation (PARF) C06-01 grant. P.P. Pramstaller, I. Pichler, S.S. Park, A. Quattrone, and E. Rogaeva report no disclosures. O.A. Ross is funded by NIH/NINDS awards P50 NS072187 and R01 NS078086, and the Michael J Fox Foundation. L. Stefanis has received a grant for genetic studies of PD from the Hellenic Secretariat of Research and Technology (PENED 2003), in which Novartis Hellas acted as a co-sponsor. J.D. Stockton reports no disclosures. W. Satake receives research support from Japan Intractable Disease Research Foundation. P.A. Silburn and J. Theuns report no disclosures. E.-K. Tan is funded by National Medical Research Council, Duke-NUS Graduate Medical School, and Singapore Millennium Foundation. He has received honoraria from Novartis, Boehringer Ingelheim, and GSK. T. Toda receives research support from Ministry of Health, Labour and Welfare of Japan. H. Tomiyama reports no disclosures. R.J. Uitti has received research funding from the NIH, PARRF, PSG, Noscira, Inc. and Advanced Neuromodulation Systems, Inc. Dr. Uitti has served as a Continuing Medical Educator for the AAN. His institution has received annual royalties from the licensing of the technology related to PARK8/LRRK2 greater than the federal threshold for significant financial interest. Dr. Uitti has not received any royalties. Dr. Uitti receives an honorarium as Associate Editor of Neurology®. K. Wirdefeldt reports no disclosures. Z. Wszolek holds and has contractual rights for receipt of future royalty payments from patents re: A novel polynucleotide involved in heritable Parkinson's disease, receives educational research support from Allergan, Inc., the NIH/NINDS 1RC2NS070276, NS057567, P50NS072187, Mayo Clinic Florida (MCF) Research Committee CR programs (MCF #90052018 and MCF #90052030), and the gift from Carl Edward Bolch, Jr. and Susan Bass Bolch (MCF #90052031/PAU #90052). G. Xiromerisiou, K.-C. Yueh, and Y. Zhao report no disclosures. T. Gasser is funded by Novartis Pharma, the Federal Ministry of Education and Research (BMBF) (NGFN-Plus and ERA-Net NEURON), the Helmholtz Association (HelMA, Helmholtz Alliance for Health in an Ageing Society), and the European Union (MeFoPa, Mendelian Forms of Parkinsonism). He received speaker honoraria from Novartis, Merck-Serono, Schwarz Pharma, Boehringer Ingelheim, and Valeant Pharma and royalties for his consulting activities from Cefalon Pharma and Merck-Serono. Dr. Gasser holds a patent concerning the LRRK2 gene and neurodegenerative disorders. D.M. Maraganore received funding support from the National Institutes of Health grant ES10751 (“Molecular Epidemiology of Parkinson's Disease”). He also received funding support from Alnylam Pharmaceuticals and Medtronic, Inc. to conduct an observational study of Parkinson's disease outcomes. Dr. Maraganore had a patent filed for a method to treat Parkinson disease. It has been licensed to Alnylam Pharmaceuticals. R. Krüger has received research grants of the German Research Council (DFG; KR2119/3-2), the Michael J Fox Foundation, and the Federal Ministry for Education and Research (BMBF, NGFNplus; 01GS08134), as well as speaker honoraria and/or travel grants from UCB Pharma, Cephalon, Abbott Pharmaceuticals, Takeda Pharmaceuticals, and Medtronic. Go to Neurology.org for full disclosures.
1. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009; 461: 747– 753. [PMC free article] [PubMed]
2. McCarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev 2008; 9: 356– 369 . [PubMed]
3. Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009; 41: 1308– 1312. [PMC free article] [PubMed]
4. Maraganore DM, de Andrade M, Lesnick TG, et al. High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet 2005; 77: 685– 693. [PubMed]
5. Pankratz N, Wilk JB, Latourelle JC, et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 2009; 124: 593– 605. [PMC free article] [PubMed]
6. Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009; 41: 1303– 1307. [PubMed]
7. Saad M, Lesage S, Saint-Pierre A, et al. Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. Hum Molecul Genet 20: 615– 627. [PubMed]
8. Spencer CC, Plagnol V, Strange A, et al. Dissection of the genetics of Parkinson's disease identifies an additional association 5′ of SNCA and multiple associated haplotypes at 17q21. Hum Molecul Genet 20: 345– 353. [PMC free article] [PubMed]
9. Hamza TH, Zabetian CP, Tenesa A, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 42: 781– 785. [PMC free article] [PubMed]
10. Maraganore DM, de Andrade M, Elbaz A, et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006; 296: 661– 670. [PubMed]
11. Simon-Sanchez J, van Hilten JJ, van de Warrenburg B, et al. Genome-wide association study confirms extant PD risk loci among the Dutch. Eur J Hum Genet 2011; 19: 655– 661. [PMC free article] [PubMed]
12. Mata IF, Yearout D, Alvarez V, et al. Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for Parkinson's disease. Mov Disord 2011; 26: 819– 823. [PMC free article] [PubMed]
13. Simon-Sanchez J, van Hilten JJ, van de Warrenburg B, et al. Genome-wide association study confirms extant PD risk loci among the Dutch. Eur J Hum Genet 2011; 19: 655– 661. [PMC free article] [PubMed]
14. Nalls MA, Plagnol V, Hernandez DG, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011; 377: 641– 649. [PubMed]
15. Ioannidis JP, Thomas G, Daly MJ. Validating, augmenting and refining genome-wide association signals. Nat Rev 2009; 10: 318– 329 . [PubMed]
16. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539– 1558. [PubMed]
17. Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ 2007; 335: 914– 916. [PMC free article] [PubMed]
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557– 560. [PMC free article] [PubMed]
19. Clarke GM, Cardon LR. Aspects of observing and claiming allele flips in association studies. Genet Epidemiol 2010; 34: 266– 274. [PubMed]
20. Rhodes SL, Sinsheimer JS, Bordelon Y, Bronstein JM, Ritz B. Replication of GWAS associations for GAK and MAPT in Parkinson's disease. Ann Hum Genet 2011; 75: 195– 200. [PMC free article] [PubMed]
21. Do CB, Tung JY, Dorfman E, et al. Web-based genome-wide association study identifies two novel Loci and a substantial genetic component for Parkinson's disease. PLoS Genet 2011; 7: e1002141. [PMC free article] [PubMed]
22. Nalls MA, Plagnol V, Hernandez DG, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011; 377: 641– 649. [PubMed]
23. Ioannidis JP, Patsopoulos NA, Evangelou E. Heterogeneity in meta-analyses of genome-wide association investigations. PloS One 2007; 2: e841. [PMC free article] [PubMed]
24. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994; 309: 1351– 1355. [PMC free article] [PubMed]
25. Lewis SJ, Foltynie T, Blackwell AD, Robbins TW, Owen AM, Barker RA. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 2005; 76: 343– 348. [PMC free article] [PubMed]
26. Wang K, Li M, Hakonarson H. Analysing biological pathways in genome-wide association studies. Nat Rev Genet 2010; 11: 843– 854. [PubMed]
27. Fuchs J, Nilsson C, Kachergus J, et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007; 68: 916– 922. [PubMed]
28. Scholz SW, Houlden H, Schulte C, et al. SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol 2009; 65: 610– 614. [PMC free article] [PubMed]
29. Zody MC, Jiang Z, Fung HC, et al. Evolutionary toggling of the MAPT 17q21.31 inversion region. Nat Genet 2008; 40: 1076– 1083. [PMC free article] [PubMed]
30. Ioannidis JP, Ntzani EE, Trikalinos TA. ‘Racial' differences in genetic effects for complex diseases. Nat Genet 2004; 36: 1312– 1318. [PubMed]
Articles from Neurology are provided here courtesy of
American Academy of Neurology